Activation of microglia, CNS resident immune cells, is a pathological hallmark of amyotrophic lateral sclerosis (ALS), a neurodegenerative disorder affecting motor neurons. Despite evidence that microglia contribute to disease progression, the exact role of these cells in ALS pathology remains unknown. We immunomagnetically isolated microglia from different CNS regions of SOD1 G93A rats at three different points in disease progression:
Introduction
ALS is a neurodegenerative CNS disorder that selectively affects motor neurons, resulting in a progressive loss of motor function, paralysis and death. Although disease etiology is unknown, genetic mutations are associated with familial forms of ALS, including mutations in Cu/Zn superoxide dismutase-1 (SOD1; (Rosen et al., 1993) ). Overexpression of mutant human SOD1 in animal models results in motor neuron disease. Some studies suggest that this pathology is driven by a non-cell autonomous toxicity mediated by astrocytes, neurons or microglia (Boillee et al., 2006a; Dibaj et al., 2011; Ilieva et al., 2009) .
A hallmark of ALS pathology is microglial activation and proliferation (Beers et al., 2006 (Beers et al., , 2011 Fendrick et al., 2007; Philips and Robberecht 2011; Sanagi et al., 2010) . Microglia are innate immune cells permanently residing in the CNS responsible for maintaining CNS homeostasis; however, their exact role in the ALS pathology or the mechanisms whereby microglia are activated have not yet been identified. Several lines of evidence indicate that while microglia do not significantly contribute to disease onset, they accelerate disease progression (Beers et al., 2006; Boillee et al., 2006b; Ilieva et al., 2009; Lee et al., 2012) . Although microglial morphological activation is often interpreted as neuroinflammation, mostly based on in vitro studies or in vivo studies examining inflammatory markers in tissue homogenates (Beers et al., 2011; Hensley et al., 2003; Xie et al., 2004) , there is little direct evidence that microglia are polarized toward the pro-inflammatory M1 phenotype in this disease in vivo. One recent study reported increased microglial expression of NOX2, but not other M1 markers, in SOD1 mutant mice (Liao et al., 2012) . The failure of clinical trials targeting neuroinflammation in ALS (Benatar 2007; Cudkowicz et al., 2006; Gordon et al., 2007; Werdelin et al., 1990) suggests that a better understanding of microglial activities in ALS is needed. 
